- Home
- Companies
- AVITA Medical
- Services
- AVITA - Treatment of Stable Vitiligo
AVITA - Treatment of Stable Vitiligo
Vitiligo is a disease affecting approximately 6.5 million people in the U.S. resulting in loss of color, or pigmentation, in patches of skin that impacts the quality of life for those living with the condition. Ongoing research with the RECELL® System for the treatment of skin defects, such as vitiligo and dermatological diseases, helps share experiences among the medical community. Below is a case study provided as background.
Submitted Investigational Device Exemption (IDE) to FDA in May 2020 to determine safety and effectiveness of the RECELL® System for repigmentation of stable vitiligo lesions.
Received FDA IDE approval in December 2019 for a feasibility study to evaluate the RECELL® System and Melanocyte Keratinocyte Transplantation Procedure (MKTP) for repigmentation of stable vitiligo lesions.